Harbor–UCLA Medical Center

Running trials

• Recruiting

  Deployment of a Novel National Institute of Neurological Disorders and Stroke Clinical, Biomarker, Imaging, and Modifiers (CBI-M) Classification Framework for Emergency Department Patients With Glasgow Coma Scale 15 Traumatic Brain Injury (PIONEER-Prognosis)

  NCT07858266· University of Michigan· Source

• Recruiting

  Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

  NCT07369024· Phase 2· Mohsen Saidinejad· Source

• Recruiting

  A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

  NCT07421167· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

  NCT07285460· Phase 3· Sanofi· Source

• Recruiting

  Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

  NCT07007962· Phase 3· Sanofi· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Recruiting

  A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

  NCT06979362· Phase 2· Novo Nordisk A/S· Source

• Recruiting

  XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

  NCT06959641· Phase 2· Jochen Lorch· Source

• Recruiting

  A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

  NCT06612268· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization

  NCT06550024· CrannMed· Source

• Recruiting

  Starting Technology in At Risk Type 1 Diabetes Study

  NCT06453928· University of California, Los Angeles· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

  NCT06096779· Phase 2· Genentech, Inc.· Source

• Active, not recruiting

  Reducing Blood Pressure in Patients With High Cardiovascular Risk

  NCT05937685· University of Southern California· Source

• Recruiting

  Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry

  NCT05880537· LifeNet Health· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

  NCT04895241· Phase 3· Biogen· Source

• Active, not recruiting

  SELUTION SLR™ 014 In-stent Restenosis

  NCT04280029· M.A. Med Alliance S.A.· Source

• Active, not recruiting

  Reducing Lung CongestIon Symptoms in Advanced Heart Failure

  NCT03499236· V-Wave Ltd· Source

• Active, not recruiting

  ADAPT - A Patient Registry of the Real-world Use of Orenitram®

  NCT03045029· United Therapeutics· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Immune thrombocytopenia (ITP)2 recruiting
• Sickle cell disease2 recruiting
• Chronic kidney disease1 recruiting
• Haemophilia1 recruiting
• Heart failure1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple sclerosis1 recruiting
• Stroke1 recruiting
• Thyroid cancer1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Terminated

  REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

  NCT06237309· Phase 2· Regeneron Pharmaceuticals· Source

• Completed

  Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

  NCT04918719· Phase 2· Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center· Source

• Completed

  Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

  NCT05405114· Phase 2· Novo Nordisk A/S· Source

• Completed

  Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD

  NCT05326412· Phase 2· Sanofi· Source

• Completed

  Evaluation in STEMI Patients Using FDY-5301

  NCT04837001· Phase 3· Faraday Pharmaceuticals, Inc.· Source

• Completed

  Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

  NCT05130268· Phase 4· American Heart Association· Source

• Completed

  Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

  NCT04873934· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)

  NCT01534819· Medtronic Cardiovascular· Source